Emory Vaccine and Treatment Evaluation Unit - DMID 20-0034
$669,970UM1FY2021AINIH
Emory University, Atlanta GA
Investigators
Linked publications & trials
Paper 39774938Paper 39158584Paper 39040211Paper 38876903Paper 38780941Paper 38657001Paper 38598658Paper 38408357Paper 38332733Paper 37561027Paper 37440227Paper 37433788Paper 37385888Paper 37205592Paper 37036397Paper 36689221Paper 35898343Paper 35818363Paper 35798000Paper 35675197Paper 35617986Paper 35590141Paper 35547849Paper 35544369Paper 35139271Paper 35090580Paper 35081293Paper 35029629Paper 34981072Paper 34907214Paper 34672949Paper 34671773Paper 34549975Paper 34545372Paper 34519540Paper 34494017Paper 34409989Paper 34385356Paper 34379740Paper 34278310Paper 34103407Paper 34031659Paper 33882225Paper 33880474Paper 33822494Paper 33798491Paper 33774551Paper 33378609Paper 33306283Paper 33270381Paper 32991794Paper 32663912Paper 32445440
Abstract
Summary/Abstract The Emory VTEU has proven essential in the fight against the pandemic. This supplement will allow for further investigations into second generation vaccines trials (20-0034). 1
View original record on NIH RePORTER →